Sesques P, Houot R, Al Tabaa Y, Le Bras F, Ysebaert L, Choquet S, Jardin F, Bay JO, Gros FX, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, La Rochelle LD, Feugier P, Marcais A, Griolet S, Tarte K, Laurent C, Cartron G

Haematologica. 2026 05 21;:

Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.

Decazes P, Rossi C, Sesques P, Becker S, Viennot M, Mihailescu SD, Lemonnier F, Durot E, Gower N, Willaume A, Obéric L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Dû K, Bonnet C, Bailly S, Damaj GL, Laribi K, Morineau N, Houot R, Chauchet A, Jardin F, Tilly H, Veresezan EL, Drieux F, Donzel M, Traverse-Glehen A, Tonnelet D, Camus V

Blood Adv. 2026 05 12;:

Diverse roles of YTHDC1 in chromatin and blood cancers.

Pernon B, Benchikh Y, Fournier C, Delforge M, Dumétier B, Delva L, Durand A, Rossi C, Martin L, Guidez F, Verdel A, Aucagne R, Callanan MB

Front Genet. 2026 05 8;17:1773468

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.

Sesques P, Manson G, Cartron G, Gros FX, Morschhauser F, Castilla-Llorente C, Brisou G, Bories P, Thieblemont C, Drieu La Rochelle L, Tessoulin B, André A, Rossi C, Paillassa J, Guidez S, Capes A, Herbreteau L, Choquet S, Bay JO, Chauchet A, Lebras L, Claves F, Abraham J, Malfuson JV, Rubio MT, Decroocq J, Fornecker LM, Damaj G, Fouillet L, Joris M, Loschi M, Hermine O, Hafirassou H, Zele EV, Dupont V, Gouill SL, Houot R, Camus V

Hemasphere. 2026 05;10(5):e70356

Patient-Derived Lymphoma Spheroids Reveal Predictive Markers of Glofitamab Resistance in Relapsed/Refractory B-NHL.

Marcoux P, Gava F, Tosolini M, Gravelle P, Schniederjohann C, Quertinmont S, Serrat N, Bouquet F, Herter S, Tarte K, Roussel M, Sesques P, Bret C, Rossi C, Aubert P, Morschhauser F, Cartron G, Huber W, Dietrich S, Ysebaert L, Brousset P, Bruch PM, Pérez-Galán P, Bezombes C, Laurent C

Blood. 2026 02 26;:

Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials.

Letailleur V, Chaillol I, Cherblanc F, Ghesquières H, Peyrade F, Guidez S, Bijou F, Sesques P, Rossi C, Fornecker LM, Fouillet L, Carras S, Chartier L, Belot A, Oberic L, Jardin F, Tessoulin B

Blood Cancer J. 2025 11 3;15(1):190

Risk stratification of diffuse large B-cell lymphoma patients using plasma NMR-based metabolomics at diagnostic.

Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquieres H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Obéric L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud VI

Blood Adv. 2025 10 7;:

Impact of socioeconomic individual and ecological factors on extreme diagnosis-to-treatment interval in diffuse large B-Cell lymphoma in the French real-world cohort REALYSA.

Cantrelle C, Belot A, Monnereau A, Bijou F, Rossi C, Bommier C, Hafirassou HK, Fouillet L, Ghesquières H, Ysebaert L, Le Guyader Peyrou S

Cancer Epidemiol. 2025 08 14;98:102875

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell Lymphoma.

Penichoux J, Decazes P, Rossi C, Sesques P, Haioun C, Durot E, Gower N, Willaume A, Oberic L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Houot R, Chauchet A, Becker S, Tonnelet D, Tilly H, Jardin F, Lévêque E, Camus V

Hematol Oncol. 2025 07;43(4):e70117

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment.

Claudel A, Cottereau AS, Bachy E, Itti E, Feugier P, Rossi C, Lemonnier F, Camus V, Daguindau N, Cartron G, Nicolas Virelizier E, Mbouma DL, Cardoso C, Bommier C, Tessoulin B, Fruchart C, Gilbert A, Durot E, Fleck E, Pica GM, Zerazhi H, Guidez S, Cheminant M, Sarkozy C, Xerri L, Vercellino L, Trabelsi N, Gomes L, Portugues C, Viailly PJ, Delfau-Larue MH, Morschhauser F

Blood. 2025 06 11;:

Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma).

Le Dû K, Chauchet A, Sadot-Lebouvier S, Fitoussi O, Fontanet B, Saint-Lezer A, Maloisel F, Rossi C, Carras S, Parcelier A, Balavoine M, Septans AL

JMIR Cancer. 2025 05 6;11:e65960

Are oldest old patients with diffuse large B-cell lymphoma different than their younger counterparts: Results from the REALYSA real-life cohort.

Cantrelle C, Belot A, Monnereau A, Bijou F, Rossi C, Khebbeb Hafirassou H, Fouillet L, Soubeyran P, Ghesquières H, Ysebaert L, Le Guyader Peyrou S, Galvin A

Cancer Epidemiol. 2025 04 5;96:102812

High Fluorescent Lymphoid Cell Levels Assessed on Initial Blood Count in Newly Diagnosed Multiple Myeloma Carry Prognostic Significance.

Aramon Y, Pieragostini A, Francin PJ, Chrétien ML, Lafon I, Caillot D, Bailly F, Bastie JN, Rossi C, Maynadié M, Guy J

EJHaem. 2025 04;6(2):e1095

Interim PET after 4 Cycles Predicts Outcome in Histomolecularly Confirmed Primary Mediastinal B-Cell Lymphoma.

Camus V, Molina TJ, Desmots F, Blanc-Durand P, Kanoun S, Moslemi A, Ruminy P, Le Gouill S, Ghesquieres H, Obéric L, Morschhauser F, Tilly H, Ribrag V, Houot R, Thieblemont C, Maisonneuve HG, Claves F, Bouabdallah K, Haioun C, Damaj G, Fornecker LM, Noel R, Feugier P, Sibon D, Cartron G, Bonnet C, Bernard W, Kraeber-Bodere F, Bodet-Milin C, Jais JP, Briere J, Rossi C, Elsensohn MH, Chartier L, Itti E, Jardin F, Fest T

Blood Adv. 2025 03 3;:

Health-Related Quality of Life in Long-Term Survivors of Non-Hodgkin Lymphoma: A French Population-Based Study.

Wasse SK, Assogba E, Orazio S, Atsou KM, Rossi C, Guilloteau A, Gauthier S, Girard S, Poncet JM, Damaj G, Troussard X, Monnereau A, Dabakuyo-Yonli ST, Maynadie M

Cancers (Basel). 2025 02 19;17(4):

Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.

Bommier C, Donzel M, Rossi C, Fornecker LM, Bijou F, Chauchet A, Lebras L, Ysabaert L, Haioun C, Bouabdallah K, Gastinne T, Morineau N, Amorim S, Jardin F, Abraham J, Lamy de la Chapelle T, Gressin R, Fouillet L, Fruchart C, Olivier G, Morschhauser F, Cherblanc F, Belot A, Le Guyader S, Monnereau A, Ghesquieres H, Thieblemont C

Hematol Oncol. 2024 11;42(6):e3314

Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines.

Rossi C, Manson G, Marouf A, Cabannes-Lamy A, Nicolas-Virelizier E, Maerevoet M, Alcantara M, Molina L, Ceraulo A, Poirée M, Galtier J, Diop N, Delette C, Segot A, Dubois S, Waultier A, Bernard S, Noël R, Guidez S, Kohn M, Bailly S, Moatti H, Touati M, Renaud L, Kanoun S, Cottereau AS, Kirova Y, Peignaux K, Dourthe ME, Simonin M, Leblanc T, Quéro L, Krzisch D, Duléry R, Grenier A, Gastinne T, Casasnovas O, Gallamini A, André M, Morschhauser F, Deau B, Fornecker LM, Ghesquières H

Eur J Cancer. 2024 10 22;213:115073

Identification of primary mediastinal B-cell lymphomas with higher clonal dominance and poorer outcome using 5' RACE.

Camus V, Viennot M, Viailly PJ, Drieux F, Veresezan EL, Bobée V, Rainville V, Bohers E, Sesques P, Haioun C, Durot E, Bayaram M, Rossi C, Martin L, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Gower N, Willaume A, Antier C, Renaud L, Leveque E, Decazes P, Becker S, Tonnelet D, Gaulard P, Tilly H, Molina T, Traverse-Glehen A, Donzel M, Ruminy P, Jardin F

Blood Adv. 2024 09 18;:

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H

Eur J Cancer. 2024 07 4;208:114210

How to treat advanced Hodgkin lymphoma?

Rossi C, Casasnovas RO

Curr Opin Oncol. 2024 06 26;:

Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling.

Alig SK, Esfahani MS, Garofalo A, Li MY, Rossi C, Flerlage T, Flerlage JE, Adams R, Binkley MS, Shukla N, Jin MC, Olsen M, Telenius A, Mutter JA, Schroers-Martin JG, Sworder BJ, Rai S, King DA, Schultz A, Bögeholz J, Su S, Kathuria KR, Liu CL, Kang X, Strohband MJ, Langfitt D, Pobre-Piza KF, Surman S, Tian F, Spina V, Tousseyn T, Buedts L, Hoppe R, Natkunam Y, Fornecker LM, Castellino SM, Advani R, Rossi D, Lynch R, Ghesquières H, Casasnovas O, Kurtz DM, Marks LJ, Link MP, André M, Vandenberghe P, Steidl C, Diehn M, Alizadeh AA

Nature. 2023 12 11;:

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.

Ghesquieres H, Cherblanc F, Belot A, Micon S, Bouabdallah K, Esnault C, Fornecker LM, Thokagevistk K, Bonjour M, Bijou F, Haioun C, Morineau N, Ysebaert L, Damaj G, Tessoulin B, Guidez S, Morschhauser F, Thieblemont C, Chauchet A, Gressin R, Jardin F, Fruchart C, Labouré G, Fouillet L, Lionne-Huyghe P, Bonnet A, Lebras L, Amorim S, Leyronnas C, Olivier G, Guieze R, Houot R, Launay V, Drénou B, Fitoussi O, Detourmignies L, Abraham J, Soussain C, Lachenal F, Pica GM, Fogarty P, Cony-Makhoul P, Bernier A, Le Guyader-Peyrou S, Monnereau A, Boissard F, Rossi C, Camus V

Blood Adv. 2023 10 24;:

High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.

Camus V, Viailly PJ, Drieux F, Veresezan EL, Sesques P, Haioun C, Durot E, Patey M, Rossi C, Martin L, Rainville V, Bohers E, Ruminy P, Penther D, Kaltenbach S, Bruneau J, Paillassa J, Tournilhac O, Willaume A, Antier C, Lazarovici J, Leveque E, Decazes P, Becker S, Tonnelet D, Berriolo-Riedinger A, Gaulard P, Tilly H, Molina TJ, Traverse-Glehen A, Jardin F

Blood Adv. 2023 10 20;:

Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.

Faria C, Gava F, Gravelle P, Valero JG, Dobaño-López C, Van Acker N, Quelen C, Jalowicki G, Morin R, Rossi C, Lagarde JM, Fournié JJ, Ysebaert L, Laurent C, Pérez-Galán P, Bezombes C

J Immunother Cancer. 2023 10;11(10):

Impact of a Tripartite Collaboration between Oncologist, Pharmacist and Diabetologist in the Management of Patients with Diabetes Starting Chemotherapy: The ONCODIAB Trial.

Paris J, Legris P, Devaux M, Bost S, Gueneau P, Rossi C, Manfredi S, Bouillet B, Petit JM, Pistre P, Boulin M

Cancers (Basel). 2023 09 13;15(18):

Factors Affecting Health-Related Quality of Life among Survivors of Non-Hodgkin Lymphoma: A Population-Based Study.

Wasse SK, Mounier M, Assogba E, Rossi C, Adnet J, Gauthier S, Girard S, Atsou KM, Dabakuyo-Yonli TS, Maynadie M

Cancers (Basel). 2023 07 30;15(15):

Comparison of machine learning approaches for POD24 prediction based on pretreatment PET in follicular lymphoma patients (on behalf of CALYM/LYSA groups)

Hoang DT, Schalck E, Ricci R, Chartier L, Marlot L, Gomez E, Nadel B, Xerri L, Morschhauser F, Kanoun S, Rossi C

Hematol Oncol. 2023 06;41 Suppl 2:340

Distinct molecular determinants of treatment-failure in elderly Hodgkin lymphoma identified by cell-free DNA profiling: A LYSA Study

Rossi C, Boegeholz JL, Alig SK, Garofolo A, Esfahani MS, Schroers-Martin J, Olsen M, Kang X, Kurtz DM, Sugio T, Hamilton MP, André M, Casasnovas O, Diehn M, Ghesquières H, Alizadeh AA

Hematol Oncol. 2023 06;41 Suppl 2:321-322

[Frontline therapy for classical Hodgkin lymphoma patients].

Rossi C, Casasnovas O

Rev Prat. 2023 06;73(6):625-632

Tandem haematopoietic stem cell transplantation versus single cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA.

Marouf A, Molinari N, Sibon D, Cottereau AS, Kanoun S, Antoine C, Debureaux PE, Cavalieri D, Fornecker LM, Casasnovas RO, Herbaux C, Amorim S, Rossi C, Bouscary D, Brice P, Ghesquieres H, Tamburini J, Deau B

Br J Haematol. 2023 05 16;:

Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab.

Rodier C, Kanagaratnam L, Morland D, Herbin A, Durand A, Chauchet A, Choquet S, Colin P, Casasnovas RO, Deconinck E, Godard F, Delmer A, Rossi C, Durot E

Hemasphere. 2023 05;7(5):e861

Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.

Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L, Roche L, Giorgi R, Gauthier S, Girard S, Böckle J, Wasse SK, Rachou H, Bouzid L, Poncet JM, Orazio S, Monnereau A, Troussard X, Mounier M, Maynadie M

Cancer Med. 2023 01 29;:

Influence of Sociodemographic Determinants on the Hodgkin Lymphoma Baseline Characteristics in Long Survivors Patients Enrolled in the Prospective Phase 3 Trial AHL2011.

Chevreux S, de Barros S, Laurent C, Durand A, Delpierre C, Robert P, Joubert C, Griolet S, Kanoun S, Bastie JN, Casasnovas RO, Rossi C

Cancers (Basel). 2022 12 22;15(1):

Repeat Element Activation-Driven Inflammation: Role of NFκB and Implications in Normal Development and Cancer?

Dumetier B, Sauter C, Hajmirza A, Pernon B, Aucagne R, Fournier C, Row C, Guidez F, Rossi C, Lepage C, Delva L, Callanan MB

Biomedicines. 2022 12 1;10(12):

Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.

Lamaison C, Ferrant J, Gravelle P, Traverse-Glehen A, Ghesquières H, Tosolini M, Rossi C, Ysebaert L, Brousset P, Laurent C, Syrykh C

Cancers (Basel). 2022 10 6;14(19):

Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature.

Le Dû K, Alarion N, Rabi H, Casasnovas O, Robert P, Durand A, Burlet B, Tabouret-Viaud C, Ramla S, Martin L, Rossi C

CNS Oncol. 2022 06 13;:CNS88

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: TMTV is a useful risk factor to stratify patients at baseline.

Rossi C, André M, Dupuis J, Morschhauser F, Joly B, Lazarovici J, Ghesquières H, Stamatoullas A, Nicolas-Virelizier E, Feugier P, Gac AC, Moatti H, Fornecker LM, Deau B, Joubert C, Fortpied C, Raemaekers J, Federico M, Kanoun S, Meignan M, Traverse-Glehen A, Cottereau AS, Casasnovas RO

Haematologica. 2022 05 31;:

Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients.

Devaux M, Boulin M, Mounier M, Caillot D, Ahwij N, Herbin A, Bastie JN, Favennec C, Robert P, Pistre P, Bost S, Amiot P, Jacquesson L, Casasnovas O, Rossi C, Gueneau P

Cancers (Basel). 2022 05 21;14(10):

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas.

Revailler W, Cottereau AS, Rossi C, Noyelle R, Trouillard T, Morschhauser F, Casasnovas O, Thieblemont C, Gouill SL, André M, Ghesquieres H, Ricci R, Meignan M, Kanoun S

Diagnostics (Basel). 2022 Feb 6;12(2):

Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Casasnovas RO, Bouabdallah R, Brice P, Lazarovici J, Ghesquieres H, Stamatoullas A, Dupuis J, Gac AC, Gastinne T, Joly B, Bouabdallah K, Nicolas-Virelizier E, Feugier P, Morschhauser F, Sibon D, Bonnet C, Berriolo-Riedinger A, Edeline V, Parrens M, Damotte D, Coso D, André M, Meignan M, Rossi C

J Clin Oncol. 2022 Jan 6;:JCO2101777

Outcomes after first-line immunochemotherapy for primary mediastinal B cell lymphoma patients: a LYSA study.

Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles-Moreau MP, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy MP, Besson C, Lebras L, Choquet S, Le Dû K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve HG, Houot R, Chauchet A, Jardin F, Traverse-Glehen A, Decazes P, Becker S, Berriolo-Riedinger A, Tilly H

Blood Adv. 2021 Aug 30;:

[Role of radiotherapy in haematology].

Peignaux-Casasnovas K, Truc G, Rossi C, Casasnovas O

Cancer Radiother. 2021 Aug 28;:

PD-1 inhibitors in patients with Hodgkin lymphoma.

Rossi C, Casasnovas RO

Eur J Cancer. 2021 Aug 26;:

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified.

Bourbon E, Maucort-Boulch D, Fontaine J, Mauduit C, Sesques P, Safar V, Ferrant E, Golfier C, Ghergus D, Karlin L, Lazareth A, Bouafia F, Pica GM, Orsini-Piocelle F, Rocher C, Gros FX, Parrens M, Dony A, Rossi C, Ghesquières H, Bachy E, Traverse-Glehen A, Sarkozy C

Blood Adv. 2021 Aug 24;5(16):3227-3239

Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.

Duléry R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, Rossi C, Drenou B, Deau Fischer B, Soussain C, Feugier P, Noël N, Choquet S, Bologna S, Joly B, Philippe L, Kohn M, Malak S, Fouquet G, Daguindau E, Taoufik Y, Lacombe K, Cartron G, Thiéblemont C, Besson C

Am J Hematol. 2021 Apr 28;:

3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma.

Gava F, Faria C, Gravelle P, Valero JG, Dobaño-López C, Morin R, Norlund M, Gomes A, Lagarde JM, Rossi C, Bordenave J, Pieruccioni L, Rouquette J, Matas-Céspedes A, Fournié JJ, Ysebaert L, Laurent C, Pérez-Galán P, Bezombes C

Cancers (Basel). 2021 Mar 24;13(7):

A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort

Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, Bijou F, Sujobert P, Fabbro-Peray P, Bernier A, Belot A, Chartier L, Fornecker LM, Baldi I, Bouabdallah K, Laurent C, Oberic L, Morineau N, Le Gouill S, Morschhauser F, Haioun C, Damaj G, Guidez S, Labouré G, Fitoussi O, Lebras L, Gressin R, Salles G, Ysebaert L, Monnereau A

BMC Public Health. 2021 Mar 2;21(1):432

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia.

Herbaux C, Kornauth C, Poulain S, Chong SJF, Collins MC, Valentin R, Hackett L, Tournilhac O, Lemonnier F, Dupuis J, Daniel A, Tomowiak C, Laribi K, Renaud L, Roos-Weil D, Rossi C, Van Den Neste EW, Leyronnas C, Merabet F, Malfuson JV, Tiab M, Ysebaert L, Ng SY, Morschhauser F, Staber PB, Davids MS

Blood. 2021 Feb 17;:

Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21).

Burlet B, Ramla S, Fournier C, Abrey-Recalde MJ, Sauter C, Chrétien ML, Rossi C, Duffourd Y, Ragot S, Buriller C, Tournier B, Chapusot C, Nadal N, Racine J, Guy J, Bailly F, Martin L, Casasnovas O, Bastie JN, Caillot D, Albuisson J, Broccardo C, Thieblemont C, Delva L, Maynadié M, Aucagne R, Callanan MB

Cold Spring Harb Mol Case Stud. 2021 Feb;7(1):

Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma.

Rossi C, Tosolini M, Gravelle P, Pericart S, Kanoun S, Evrard S, Gilhodes J, Franchini DM, Amara N, Syrykh C, Bories P, Oberic L, Ysebaert L, Martin L, Ramla S, Robert P, Tabouret-Viaud C, Casasnovas RO, Fournié JJ, Bezombes C, Laurent C

Haematologica. 2020 Dec 17;Online ahead of print:0

First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.

Laude MC, Lebras L, Sesques P, Ghesquieres H, Favre S, Bouabdallah K, Croizier C, Guieze R, Drieu La Rochelle L, Gyan E, Chin R, Aurran-Schleinitz T, Marouf A, Deau-Fischer B, Coppo P, Malot S, Roussel X, Chauchet A, Schwarz M, Bescond C, Lamy de la Chapelle T, Bussot L, Carras S, Burlet B, Rossi C, Daniel A, Morschhauser F, Subtil F, Michallet AS

Am J Hematol. 2020 Dec 11;:

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D'Aveni-Piney M, Obéric L, Bodet-Milin C, Bories P, Olivier P, Lafon I, Berriolo-Riedinger A, Galli E, Bernard S, Rubio MT, Bossard C, Meignin V, Merlet P, Feugier P, Le Gouill S, Ysebaert L, Casasnovas O, Meignan M, Chevret S, Thieblemont C

Blood Adv. 2020 Nov 24;4(22):5607-5615

CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.

Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, Morel G, Lagrange E, Magy L, Créange A, Michaud M, Franques J, Echaniz-Laguna A, Antoine JC, Baron M, Arnulf B, Puma A, Delmont E, Maisonobe T, Leblond V, Roos-Weil D

Blood. 2020 Nov 19;136(21):2428-2436

Ibrutinib, Obinutuzumab And Venetoclax In Relapsed and Untreated Patients with Mantle-Cell Lymphoma, a phase I/II trial.

Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, Bodet-Milin C, Ragot S, Bossard C, Nadal N, Herbaux C, Tessoulin B, Tchernonog E, Rossi C, McCulloch R, Gastinne T, Mary CB, Rule S

Blood. 2020 Nov 12;:

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study.

Lamure S, Duléry R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, Drenou B, Soussain C, Rossi C, Noël N, Choquet S, Bologna S, Joly B, Kohn M, Malak S, Fouquet G, Daguindau E, Bernard S, Thiéblemont C, Cartron G, Lacombe K, Besson C

EClinicalMedicine. 2020 Oct 13;:100549

Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy.

Bordes J, Incerti S, Mora-Ramirez E, Tranel J, Rossi C, Bezombes C, Bordenave J, Bardiès M, Brown R, Bordage MC

Med Phys. 2020 Oct;47(10):5222-5234

Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department.

de Grégori J, Pistre P, Boutet M, Porcher L, Devaux M, Pernot C, L Chrétien M, Rossi C, Manfredi S, Dalac S, Gueneau P, Boulin M

J Oncol Pharm Pract. 2020 Apr 16;:1078155220915763

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.

Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, Rossi C, Valero JG, Serrat N, Sanjuan-Pla A, Menéndez P, Roué G, López-Guillermo A, Giné E, Campo E, Colomer D, Bezombes C, van Bueren JL, Chiu C, Doshi P, Pérez-Galán P

Haematologica. 2020 04;105(4):1032-1041

Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning.

Syrykh C, Abreu A, Amara N, Siegfried A, Maisongrosse V, Frenois FX, Martin L, Rossi C, Laurent C, Brousset P

NPJ Digit Med. 2020 ;3:63

PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?

Rossi C, Casasnovas O

Oncotarget. 2019 Jul 8;10(43):4354-4355

Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells.

Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, Lapeyre-Mestre M, Millevoi S, Fournié JJ

Cell Rep. 2019 01 2;26(1):94-107.e7

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma.

Decaup E, Rossi C, Gravelle P, Laurent C, Bordenave J, Tosolini M, Tourette A, Perrial E, Dumontet C, Poupot M, Klein C, Savina A, Fournié JJ, Bezombes C

Front Immunol. 2019 ;10:1943

Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.

Péricart S, Tosolini M, Gravelle P, Rossi C, Traverse-Glehen A, Amara N, Franchet C, Martin E, Bezombes C, Laurent G, Brousset P, Fournié JJ, Laurent C

Cancers (Basel). 2018 Oct 31;10(11):

Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers.

Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H

Am. J. Hematol.. 2018 Jun 8;:

[New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].

Rossi C, Bastie JN

Rev Med Interne. 2018 May 22;:

[F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives.

Kanoun S, Rossi C, Casasnovas O

Cancers (Basel). 2018 May 18;10(5):

Antibody-Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review.

Rossi C, Chrétien ML, Casasnovas RO

Target Oncol. 2018 Mar 20;:

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

Rossi C, Mounier M, Brice P, Safar V, Nicolas-Virelizier E, Rey P, Stamatoullas-Bastard A, Alcantara M, Chauchet A, Reboursière E, Filliatre L, Perrot A, Garciaz S, Salles G, Coiffier B, Ghesquières H, Casasnovas RO

Oncotarget. 2017 Oct 17;8(49):85110-85119

Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.

Bosseboeuf A, Feron D, Tallet A, Rossi C, Charlier C, Garderet L, Caillot D, Moreau P, Cardó-Vila M, Pasqualini R, Arap W, Nelson AD, Wilson BS, Perreault H, Piver E, Weigel P, Girodon F, Harb J, Bigot-Corbel E, Hermouet S

JCI Insight. 2017 Oct;2(19):

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Gravelle P, Burroni B, Péricart S, Rossi C, Bezombes C, Tosolini M, Damotte D, Brousset P, Fournié JJ, Laurent C

Oncotarget. 2017 Jul 4;8(27):44960-44975

Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT.

Oncotarget. 2017 Jul;:

[New therapy outlooks in Hodgkin lymphoma].

Rossi C, Casasnovas RO

Bull Cancer. 2017 Feb;104(2):182-194

Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins.

Bosseboeuf A, Allain-Maillet S, Mennesson N, Tallet A, Rossi C, Garderet L, Caillot D, Moreau P, Piver E, Girodon F, Perreault H, Brouard S, Nicot A, Bigot-Corbel E, Hermouet S, Harb J

Front Immunol. 2017 ;8:1347

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Reboursiere E, Le Bras F, Herbaux C, Gyan E, Clavert A, Morschhauser F, Malak S, Sibon D, Broussais F, Braun T, Fornecker LM, Garidi R, Tricot S, Houot R, Joly B, Abarah W, Choufi B, Pham AD, Gac AC, Fruchart C, Marin E, Safar V, Parcelier A, Maisonneuve H, Bachy E, Cartron G, Jaccard A, Tournilhac O, Rossi C, Schirmer L, Martignoles JA, Gaulard P, Tilly H, Damaj G,

Oncotarget. 2016 Dec 20;7(51):85573-85583

Extreme hyperferritinemia in the setting of acute myeloid leukaemia: a case report of hemophagocytic lymphohistiocytosis.

Denimal D, Ménégaut L, Rossi C, Duvillard L, Masson D

Biochem Med (Zagreb). 2016 ;26(2):255-9

Outcomes of pregnancy in patients with congenital erythrocytosis.

McMullin MF, Bento C, Rossi C, Rainey MG, Girodon F, Cario H

Br. J. Haematol.. 2015 Aug;170(4):586-8

Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Bardet V, Wagner-Ballon O, Guy J, Morvan C, Debord C, Trimoreau F, Benayoun E, Chapuis N, Freynet N, Rossi C, Mathis S, Gourin MP, Toma A, Béné MC, Feuillard J, Guérin E, ,

Haematologica. 2015 Apr;100(4):472-8

Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma.

Rossi C, Jegu J, Mounier M, Dandoit M, Colonna M, Daubisse-Marliac L, Tretarre B, Ganry O, Guizard AV, Bara S, Bouvier V, Woronoff AS, Monnereau A, Casasnovas O, Velten M, Troussard X, Maynadie M

Leuk Lymphoma. 2015 Feb 2:1-23.

Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, Legrand L, Humbert O, Casasnovas O, Brunotte F, Cochet A

PLoS One. 2015 Oct 16;10(10):e0140830

Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43

[A rare cause of pulmonary opacities: Lung localization of Waldenstrom's macroglobulinemia].

Monnet CM, Favrolt N, Bastie JN, Chretien ML, Benoit F, Rossi C, Camus P, Bonniaud P

Rev Mal Respir. 2014 Sep;31(7):632-5

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chretien ML, Bastie JN, Brunotte F, Casasnovas RO

J Nucl Med. 2014 Apr;55(4):569-73

Genetic basis of congenital erythrocytosis: mutation update and online databases.

Bento C, Percy MJ, Gardie B, Maia TM, van Wijk R, Perrotta S, Della Ragione F, Almeida H, Rossi C, Girodon F, Aström M, Neumann D, Schnittger S, Landin B, Minkov M, Randi ML, Richard S, Casadevall N, Vainchenker W, Rives S, Hermouet S, Ribeiro ML, McMullin MF, Cario H, ,Chauveau A, Gimenez-Roqueplo AP, Bressac-de-Paillerets B, Altindirek D, Lorenzo F, Lambert F, Dan H, Gad-Lapiteau S, Catarina Oliveira A, Rossi C, Fraga C, Taradin G, Martin-Nuñez G, Vitória H, Diaz Aguado H, Palmblad J, Vidán J, Relvas L, Ribeiro ML, Luigi Larocca M, Luigia Randi M, Pedro Silveira M, Percy M, Gross M, Marques da Costa R, Beshara S, Ben-Ami T, Ugo V,

Hum. Mutat.. 2014 Jan;35(1):15-26

Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?).

Bento C, Almeida H, Maia TM, Relvas L, Oliveira AC, Rossi C, Girodon F, Fernandez-Lago C, Aguado-Diaz A, Fraga C, Costa RM, Araújo AL, Silva J, Vitória H, Miguel N, Silveira MP, Martin-Nuñez G, Ribeiro ML

Eur. J. Haematol.. 2013 Oct;91(4):361-8